


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-24.69%
+2.85%
+13.04%
+11.71%
+5.59%
COR
Cencora
$358.39
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Expands stock buyback program
COR Price Performance
$335.69 (+6.76%)
$363.42 (-1.38%)
$291.4 (+22.99%)
$250.53 (+43.05%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a weak earnings

Revenue increase YoY

Income increase YoY

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
COR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
COR Street Sentiment is extremely bullish and have positive views on the near-term outlook
COR has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Jan 30, 2026
Upgrade
Overweight
Morgan Stanley
Jan 23, 2026
Upgrade
Buy
Jefferies
Dec 10, 2025
Initiate
Overweight
Barclays
Dec 02, 2025
Upgrade
Buy
Zacks
Nov 12, 2025
Reiterate
Overweight
JP Morgan
What is COR current stock price?
What are COR stock strengths?
What is COR Risk Level?
What is COR market cap and volume?
What is COR current Stock IQ?
Should I buy COR stock right now?
Is COR a Strong Buy right now?
What does a 'Strong Buy' rating mean for COR?
What does a 'Strong Sell' rating mean for COR?
What factors influence COR's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-24.69%
+2.85%
+13.04%
+11.71%
+5.59%
COR
Cencora
Current Price
$358.39

COR Price Performance
$335.69 (+6.76%)
$363.42 (-1.38%)
$291.4 (+22.99%)
$250.53 (+43.05%)
COR Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a weak earnings

Revenue increase YoY

Income increase YoY

Eps growth
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum
Activity
Activity

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
COR Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
COR Street Sentiment is extremely bullish and have positive views on the near-term outlook
COR has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 30, 2026
Upgrade
Overweight
Morgan Stanley
Jan 23, 2026
Upgrade
Buy
Jefferies
Dec 10, 2025
Initiate
Overweight
Barclays
Dec 02, 2025
Upgrade
Buy
Zacks
Nov 12, 2025
Reiterate
Overweight
JP Morgan
COR Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Expands stock buyback program
COR Latest Analysis
Cencora Stock Down Despite Q1 Earnings Beat Gross Margin Improves. COR shares slip despite Q1 EPS beat and revenues match estimates margins expand and fiscal 2026 growth guidance up.
Wed Feb 4, 2026
Cencora outlines 11.5%-13.5% operating income growth for 2026 while integrating OneOncology.
Wed Feb 4, 2026
Cencora (COR) Q1 Earnings Top Estimates. Cencora (COR) delivered earnings and revenue surprises of 0.35% and -0.04% respectively for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Wed Feb 4, 2026
Cencora Lifts 2026 Sales Outlook Despite Q1 Revenue Miss. ) on Wednesday reported its first quarter fiscal year revenue of $85.93 billion up 5.5% year-over-year below the Wall Street .Sales increased primarily due to a 5% increase in revenue within the United States Healthcare Solutions segment and a 9.6% increase in revenue within the International Healthcare Solutions segment.The drug wholesale and distribution company reported adjusted earnings of $4.08 per share .Gross profit was $3.1 billio
Wed Feb 4, 2026
Cencora gives mixed Q1 results reaffirms guidance.
Wed Feb 4, 2026
Cencora declares $0.60 dividend.
Wed Feb 4, 2026
Cencora Q1 Earnings Assessment. ) released its Q1 earnings on Wednesday February 4 2026 at 06:30 AM.Here'.s what'.s important from the earnings announcement.Cencora beat estimated earnings by 1.0% reporting an EPS of $4.08 versus an estimate of $4.05.Revenue was up $4.45 billion from the same period last year.In the previous quarter the company beat on EPS by $0.05 resulting in a 2.0% increase change in the share price ...
Wed Feb 4, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.